US Patent 9561246 Use of Odiparcil in the treatment of a mucopolysaccharidosis
Patent 9561246 was granted and assigned to Inventiva Pharma on February, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+164 characters)
Article
Patent abstract
The present invention relates to a method of treatment of a mucopolysaccharidosis with 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-β-D-xylopyranoside.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Jean-Louis Junien0
Philippe Masson0
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09561246 Use of Odiparcil in the treatment of a mucopolysaccharidosis US Patent 9561246 Use of Odiparcil in the treatment of a mucopolysaccharidosis
Infobox
Patent Number
09561246
Patent Number
9561246
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09561246 Use of Odiparcil in the treatment of a mucopolysaccharidosis
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09561246
Date of patent
February 7, 2017
Patent application number
14506239
Date Filed
October 3, 2014
Patent primary examiner
Find more entities like US Patent 9561246 Use of Odiparcil in the treatment of a mucopolysaccharidosis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.